Having trouble accessing articles? Reset your cache.

Triglyceride trouble from tumors

A team led by researchers at the University of South Floridahas found that cancer cells alterboth the amount and the type of lipid in dendritic cells, decreasing their ability to initiate immunity. The finding could explain the poor immune response seen in many cancer patients-a phenomenon that has confounded many efforts to develop vaccines against tumor antigens.

The team also included researchers from the H. Lee Moffitt Cancer Center & Research Institute, Imperial College London and the University of Pittsburgh.

Because dendritic cells (DCs) collect antigens and present them to T helper cells, they already are the targets of cancer vaccines and adjuvants. For example, Dendreon Corp.'s Provenge sipuleucel-T, the first cancer vaccine therapy approved in the U.S., is created by delivering

Read the full 1203 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers